BioSpace News Archive

AB Science SA announced that Professor Albert Ludolph, MD, PhD, will deliver a presentation on masitinib in amyotrophic lateral sclerosis to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy of Neurology 2023 Annual Meeting in Boston, USA.

Cold Spring Harbor Laboratory Professor Adrian Krainer is best known for his groundbreaking research on antisense oligonucleotides —molecules that can control protein levels in cells.

Ardelyx, Inc. (Nasdaq: ARDX) today announced multiple presentations covering additional positive clinical observations of XPHOZAH at the National Kidney Foundation (NKF) 2023 Spring Clinical Meetings, which is taking place in Austin, TX from April 11-15, 2023.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 3, 2023.

10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023.

Oncocyte Corporation, a precision diagnostics company, announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the management team will participate in two upcoming investor conferences in April 2023.

Bridge Biotherapeutics (KQ288330) announced it has dosed the first patient in its Phase 2a clinical study to evaluate the efficacy, safety, and tolerability of BBT-877 in patients with idiopathic pulmonary fibrosis (IPF).

MIM Software Inc. is proud to support the efforts of the Melbourne Theronastic Innovation Centre (MTIC) in Melbourne, Victoria as they launch the use of the Siemens Biograph Vision Quadra PET/CT, one of the few such “all-organ” scanners in the world.

Adaptive Biotechnologies Corporation today announced it has entered into a translational collaboration with Takeda to use its clonoSEQ ® Assay to assess minimal residual disease (MRD) to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.